Table 14.3.1.1
Overall Summary of Treatment-Emergent Adverse Events
Safety Population

Categories, n (%)	Placebo (N=XX)	Xanomeline Low Dose (N=XX)	Xanomeline High Dose (N=XX)
Number of subjects with at least one event			
TEAE	XX (XX.X)	XX (XX.X)	XX (XX.X)
Related TEAE	XX (XX.X)	XX (XX.X)	XX (XX.X)
Serious TEAE	XX (XX.X)	XX (XX.X)	XX (XX.X)
Related Serious TEAE	XX (XX.X)	XX (XX.X)	XX (XX.X)
TEAE Leading to Death	XX (XX.X)	XX (XX.X)	XX (XX.X)
Related TEAE Leading to Death	XX (XX.X)	XX (XX.X)	XX (XX.X)
TEAE Leading to Dose Modification [a]	XX (XX.X)	XX (XX.X)	XX (XX.X)
TEAE Leading to Treatment Discontinuation	XX (XX.X)	XX (XX.X)	XX (XX.X)

Note: TEAE=Treatment-Emergent Adverse Events
[a] Dose Modification includes Dose Reduced; Drug Interrupted in the AE action taken with study treatment.

Source dataset: adae, Generated on: DDMONYYYY:HH:MM
Program: <pid>.sas, Output: <pid><oid>.rtf, Generated on: DDMONYYYY:HH:MM